cisapride and in 1130

cisapride has been researched along with in 1130 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jin, CH; Kim, DK; Krishnaiah, M; Lee, HJ; Lee, K; Park, HJ; Park, SJ; Rao, KS; Sheen, YY; Sreenu, D; Subrahmanyam, VB	1

Other Studies

1 other study(ies) available for cisapride and in 1130

Article	Year
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/ Journal of medicinal chemistry, 2014, May-22, Volume: 57, Issue:10 Topics: Administration, Oral; Aniline Compounds; Animals; Antifibrinolytic Agents; Antineoplastic Agents; Biological Availability; Drug Discovery; HEK293 Cells; Humans; Immunotherapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Structure-Activity Relationship; Triazoles	2014

Article

Year

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/

Journal of medicinal chemistry, 2014, May-22, Volume: 57, Issue:10

Topics: Administration, Oral; Aniline Compounds; Animals; Antifibrinolytic Agents; Antineoplastic Agents; Biological Availability; Drug Discovery; HEK293 Cells; Humans; Immunotherapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Structure-Activity Relationship; Triazoles

2014